Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: aripiprazole tablets Clear all
Completed Phase 3 Interventional Results available

Aripiprazole in Children and Adolescents With Bipolar I Disorder

NCT00110461
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
53
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 4 Interventional Results available

Optimizing Outcomes of Treatment-Resistant Depression in Older Adults

NCT02960763
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
Interventions
Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation, Switch to nortriptyline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Los Angeles, California • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 3 Interventional

Study of Aripiprazole in Patients With Acute Bipolar Mania

NCT00097266
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Placebo, Aripiprazole, Haloperidol
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
15
States / cities
Anaheim, California • Cerritos, California • Garden Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

NCT01418352
View directory record Official record
Conditions
Tourette's Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
7 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Dothan, Alabama • San Francisco, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 4 Interventional

Study of Aripiprazole in Subjects With Alcoholism

NCT00082199
View directory record Official record
Conditions
Alcoholism
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
14
States / cities
Farmington, Connecticut • New Haven, Connecticut • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT01416441
View directory record Official record
Conditions
Tourette's Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
7 Years to 18 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
36
States / cities
Dothan, Alabama • Little Rock, Arkansas • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT01727700
View directory record Official record
Conditions
Tourette's Disorder, Tic Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
7 Years to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
55
States / cities
Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

NCT00337571
View directory record Official record
Conditions
Behavioral Symptoms, Autistic Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
31
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 8, 2026, 5:43 PM EDT
Terminated Phase 2Phase 3 Interventional

A Long-Term, Open-Label, Study on Schizophrenia

NCT01129674
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
42
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2013 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).

NCT00332241
View directory record Official record
Conditions
Autistic Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Boca Raton, Florida • Atlanta, Georgia • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 8, 2026, 5:43 PM EDT
Terminated Phase 4 Interventional Results available

Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder

NCT03661983
View directory record Official record
Conditions
Tourette's Disorder (TD)
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
38
States / cities
Anaheim, California • Riverside, California • Santa Ana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Sep 8, 2026, 5:43 PM EDT
Terminated Phase 4 Interventional Results available

A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

NCT03643159
View directory record Official record
Conditions
Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
Interventions
Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
Combination Product · Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Santa Rosa, California • Decatur, Georgia • Smyrna, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

NCT00802100
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Perphenazine, Aripiprazole, Metformin, Simvastatin, Benztropine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Colton, California • Palo Alto, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 4 Interventional Results available

A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode

NCT00277212
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lamotrigine + Aripiprazole, Lamotrigine + Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 55 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

NCT00845026
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, aripiprazole, olanzapine, risperidone
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00706654
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
937 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
39
States / cities
Cerritos, California • Escondido, California • Garden Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 4 Interventional

Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

NCT00080327
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Aripiprazole Open-Label, Safety and Tolerability Study

NCT00102518
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
50
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

NCT00365859
View directory record Official record
Conditions
Autistic Disorder, Behavioral Symptoms
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
55
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Aripiprazole and Effexor XR Drug Interaction Study

NCT00362271
View directory record Official record
Conditions
Healthy
Interventions
Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

NCT05402111
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

NCT03238326
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
17
States / cities
Dothan, Alabama • Anaheim, California • Culver City, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder

NCT00321516
View directory record Official record
Conditions
Bipolar Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
4
States / cities
Philadelphia, Pennsylvania • Austin, Texas • Bellaire, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 8, 2026, 5:43 PM EDT
Completed Phase 4 Interventional Results available

A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

NCT00261443
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium or Valproate with placebo (PBO), Lithium or Valproate with Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
29
States / cities
Tuscaloosa, Alabama • Anaheim, California • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 8, 2026, 5:43 PM EDT